DBV Technologies received a Buy rating following positive Phase 3 trial results for its Viaskin Peanut patch, designed to desensitize children with peanut allergies. The analyst's valuation model estimates a fair value of $42 per ADS, more than double the current share price, assuming strong market uptake and a temporary revenue peak above $1.6 billion. Key risks include potential regulatory delays and the need for additional capital, but regulatory clarity is expected soon. Long-term success depends on commercial adoption and real-world data over several years.
A USENIX Security study revealed 65,340 high-risk blockchain address misuse cases involving about 2.5 million transactions, resulting in losses exceeding $574.8 million based on May 2025 prices. Contract Account misuse caused significant losses in Et...
Rocket Lab Corporation reported a record $234.1 million in revenue for Q2 2026, marking a 62% year-over-year growth and surpassing analyst expectations. The company also achieved a record backlog of over 90 launches and secured more than $437 million...
The materials sector is currently overvalued compared to its 11-year average, with mining and metals stocks being the most overpriced. However, these stocks have high quality scores which partly offset valuation concerns. The iShares Global Materials...
The Iran conflict in early 2026 disrupted air travel to the Maldives, causing a sharp drop in tourism and forcing World Liberty Financial to postpone the MALD1 token sale linked to a Trump-branded luxury resort. This delay exposes the vulnerabilities...
A $550,000 audit contest by Sherlock uncovered 96 vulnerabilities in five upcoming XRP Ledger features, including two critical bugs that could have drained user accounts without private keys. Ripple addressed these issues before activation, highlight...
